The Effect of Duodenal, Ileal or Combined Infusion of Tastants on Food Intake

Maastricht University Medical Centre (MUMC)

Status: Completed

Conditions: Obesity

Treatments: Dietary Supplement: Placebo duodenal; Dietary Supplement: Tastants ileal; Dietary Supplement: Placebo ileal; Dietary Supplement: Tastants duodenal

Study type: Interventional

Funder types: Other

Identifiers

NCT03140930

NL59530.068.16

Details and patient eligibility

About

Rationale: The appearance of tastants in the small intestine can result in the activation of a negative feedback mechanism from different parts of the intestine to the stomach, the small intestine and to the central nervous system. These processes inhibit food processing, appetite sensations and food intake, and furthermore they increase feelings of satiety and satiation. The effects of intraduodenal and/or intraileal infusion of a combination of tastants (sweet (rebaudioside A), bitter (quinine) en umami (monosodium glutamate(MSG))) and placebo on ad libitum food intake, satiation and gastrointestinal symptoms will be investigated.

Objective: To investigate the effect of intraduodenal, intraileal and combined infusion of a combination of tastants versus infusion of placebo on food intake.

Secondary objectives:

1. To compare the effect of intraduodenal versus intraileal versus combined intraduodenal and intraileal delivery of a combination of tastants on satiation.
2. To assess the effect of intraduodenal and/or intraileal delivery of a combination of tastants on gastrointestinal symptoms/complaints.

Enrollment: 19 patients

Sex: All

Ages: 18 to 65 years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• Based on medical history and previous examination, no gastrointestinal complaints can be defined.
• Age between 18 and 65 years. This study will include healthy adult subjects (male and female). Women must be taking contraceptives.
• BMI between 18 and 25 kg/m2)
• Weight stable over at least the last 6 months

Exclusion criteria

• History of severe cardiovascular, respiratory, urogenital, gastrointestinal/ hepatic, hematological/immunologic, HEENT (head, ears, eyes, nose, throat), dermatological/connective tissue, musculoskeletal, metabolic/nutritional, endocrine, neurological/psychiatric diseases, allergy, major surgery and/or laboratory assessments which might limit participation in or completion of the study protocol. The severity of the disease (major interference with the execution of the experiment or potential influence on the study outcomes) will be decided by the principal investigator.
• Use of medication, including vitamin supplementation, except oral contraceptives, within 14 days prior to testing
• Administration of investigational drugs or participation in any scientific intervention study which may interfere with this study (to be decided by the principle investigator), in the 180 days prior to the study
• Major abdominal surgery interfering with gastrointestinal function (uncomplicated appendectomy, cholecystectomy and hysterectomy allowed, and other surgery upon judgement of the principle investigator)
• Dieting (medically prescribed, vegetarian, diabetic, microbiological, biological dynamic)
• Pregnancy, lactation
• Excessive alcohol consumption (>20 alcoholic consumptions per week)
• Smoking
• Weight <60kg
• Non-tasters of sweet, bitter or umami
• Evidence of MSG-hypersensitivity or Chinese restaurant syndrome

Trial design

Primary purpose: Prevention

Allocation: Randomized

Interventional model: Crossover Assignment

Masking: Single Blind

---

19 participants in 4 patient groups, including a placebo group

Duodenal tastants, ileal placebo

Experimental group

Description:

Duodenal infusion of combination of tastants (sweet, bitter and umami), ileal infusion of placebo (tap water)

Treatment:

Dietary Supplement: Placebo ileal

Dietary Supplement: Tastants duodenal

Duodenal placebo, ileal tastants

Experimental group

Description:

Duodenal infusion of placebo (tap water), ileal infusion of combination of tastants (sweet, bitter and umami)

Treatment:

Dietary Supplement: Placebo duodenal

Dietary Supplement: Tastants ileal

Duodenal tastants, ileal tastants

Experimental group

Description:

Duodenal infusion of combination of tastants (sweet, bitter and umami), ileal infusion of combination of tastants (sweet, bitter and umami)

Treatment:

Dietary Supplement: Tastants duodenal

Dietary Supplement: Tastants ileal

Duodenal placebo, ileal placebo

Placebo Comparator group

Description:

Duodenal infusion of placebo (tap water), ileal infusion of placebo (tap water)

Treatment:

Dietary Supplement: Placebo duodenal

Dietary Supplement: Placebo ileal